What GLP-1 trials actually found

Last updated

Results, doses and study populations, linked to the original research.

Clinicians and pharmacists who read trials like these can also be paid to judge whether AI models reason correctly about medicine: AITraining.jobs, a sister project of this site, explains what that expert review involves and how to start.

Direct comparisons

SURMOUNT-5 (nejm.org)

Peer-reviewed paper

Wegovy injection vs Zepbound

Adults with obesity, or overweight with a weight-related condition, without diabetes.

751 participants · 72 weeks (nejm.org/doi/full/10.1056/NEJMoa2416394) · Randomized, open-label

Mean weight change (% of body weight)

Treatment-regimen analysis, regardless of treatment adherence.

SURMOUNT-5: Mean weight change at 72 weeks. Treatment-regimen analysis, regardless of treatment adherence.
Treatment & doseChange
Semaglutide (Wegovy)1.7 or 2.4 mg weekly injection−13.7% (nejm.org)
Tirzepatide (Zepbound)10 or 15 mg weekly injection−20.2% (nejm.org)

Tirzepatide produced greater mean weight reduction in this trial. Both groups used their maximum tolerated dose.

This trial did not test Wegovy tablets or Wegovy HD. It was not powered to establish a safety or tolerability advantage. Study averages do not predict an individual's result.

Read the paper (nejm.org)PubMed abstract (pubmed.ncbi.nlm.nih.gov)Sponsor's analysis details (investor.lilly.com)Reviewed

SURPASS-2 (nejm.org)

Peer-reviewed paper

Ozempic injection vs Mounjaro

Adults with type 2 diabetes inadequately controlled with metformin.

1,879 participants · 40 weeks (nejm.org/doi/full/10.1056/NEJMoa2107519) · Randomized, open-label

Mean HbA1c change (percentage points)

Treatment-regimen analysis, regardless of treatment adherence or rescue therapy.

SURPASS-2: Mean HbA1c change at 40 weeks. Treatment-regimen analysis, regardless of treatment adherence or rescue therapy.
Treatment & doseChange
Semaglutide (Ozempic)1 mg weekly injection−1.86 pp (nejm.org)
Tirzepatide (Mounjaro)5 mg weekly injection−2.01 pp (nejm.org)
Tirzepatide (Mounjaro)10 mg weekly injection−2.24 pp (nejm.org)
Tirzepatide (Mounjaro)15 mg weekly injection−2.3 pp (nejm.org)

Each tirzepatide dose lowered HbA1c more than semaglutide 1 mg in this trial.

This trial did not compare Ozempic 2 mg or tablets. HbA1c changes are percentage points, not relative percentages or weight-loss results. Study averages do not predict an individual's result.

Read the paper (nejm.org)PubMed abstract (pubmed.ncbi.nlm.nih.gov)Sponsor's analysis details (investor.lilly.com)Reviewed

STEP UP (doi.org)

Peer-reviewed paper

Wegovy injection vs Wegovy HD

Adults with a BMI of at least 30, without diabetes.

1,407 participants · 72 weeks (doi.org/10.1016/S2213-8587(25)00226-8) · Randomized, double-blind, with placebo and active control

Mean weight change (% of body weight)

Treatment-policy analysis, accounting for treatment discontinuation.

STEP UP: Mean weight change at 72 weeks. Treatment-policy analysis, accounting for treatment discontinuation.
Treatment & doseChange
Semaglutide (Wegovy)2.4 mg weekly injection−15.6% (doi.org)
Semaglutide (Wegovy HD)7.2 mg weekly injection−18.7% (doi.org)
PlaceboWeekly injection−3.9% (doi.org)

The 7.2 mg dose produced greater mean weight reduction than 2.4 mg or placebo. Gastrointestinal events and altered skin sensations were more frequent at 7.2 mg.

All groups also received a lifestyle intervention. This trial did not study tablets. The 2.4 mg result is from STEP UP, not STEP 1. Study averages do not predict an individual's result.

Read the paper (doi.org)PubMed abstract (pubmed.ncbi.nlm.nih.gov)Reviewed

REDEFINE-4 (novonordisk.com)

Sponsor announcement

CagriSema vs tirzepatide

Adults with obesity and at least one associated condition.

809 participants · 84 weeks (novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html) · Randomized, open-label, non-inferiority trial

Mean weight change (% of body weight)

Treatment-regimen analysis, regardless of treatment adherence.

REDEFINE-4: Mean weight change at 84 weeks. Treatment-regimen analysis, regardless of treatment adherence.
Treatment & doseChange
CagriSema2.4 mg / 2.4 mg weekly injection−20.2% (novonordisk.com)
Tirzepatide15 mg weekly injection−23.6% (novonordisk.com)

Mean weight change (% of body weight)

Efficacy analysis, assuming treatment adherence.

REDEFINE-4: Mean weight change at 84 weeks. Efficacy analysis, assuming treatment adherence.
Treatment & doseChange
CagriSema2.4 mg / 2.4 mg weekly injection−23% (novonordisk.com)
Tirzepatide15 mg weekly injection−25.5% (novonordisk.com)

CagriSema did not meet the trial's primary non-inferiority endpoint versus tirzepatide.

Figures are from the manufacturer's headline announcement. This record does not establish peer-reviewed publication. CagriSema is investigational in our reviewed catalog. Study averages do not predict an individual's result.

Read the announcement (novonordisk.com)Reviewed

REIMAGINE 4 (sec.gov)

Sponsor announcement

CagriSema vs Mounjaro in type 2 diabetes

Adults with type 2 diabetes inadequately controlled with metformin, with or without an SGLT2 inhibitor.

1,024 participants · 68 weeks (sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm) · Randomized, open-label

Mean weight change (% of body weight)

Efficacy analysis, assuming treatment adherence.

REIMAGINE 4: Mean weight change at 68 weeks. Efficacy analysis, assuming treatment adherence.
Treatment & doseChange
CagriSema2.4 mg / 2.4 mg weekly injection−15.2% (sec.gov)
Tirzepatide (Mounjaro)15 mg weekly injection−15.8% (sec.gov)

Mean HbA1c change (percentage points)

Efficacy analysis, assuming treatment adherence.

REIMAGINE 4: Mean HbA1c change at 68 weeks. Efficacy analysis, assuming treatment adherence.
Treatment & doseChange
CagriSema2.4 mg / 2.4 mg weekly injection−1.9 pp (sec.gov)
Tirzepatide (Mounjaro)15 mg weekly injection−2.2 pp (sec.gov)

CagriSema was non-inferior to tirzepatide 15 mg for weight reduction but did not meet non-inferiority for HbA1c reduction, the trial's two primary endpoints.

Figures are from Novo Nordisk's half-year report, on the analysis that assumes every participant stayed on treatment; no treatment-regimen result or peer-reviewed publication yet. ClinicalTrials.gov lists this trial (NCT06221969) without its REIMAGINE 4 name. CagriSema is investigational. Study averages do not predict an individual's result.

Read the announcement (sec.gov)Sponsor's analysis details (clinicaltrials.gov)Reviewed

REIMAGINE 5 (novonordisk.com)

Sponsor announcement

CagriSema 1.0 mg vs Mounjaro 5 mg in type 2 diabetes

Adults with type 2 diabetes inadequately controlled on metformin, an SGLT2 inhibitor, or both.

1,023 participants · 60 weeks (novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html) · Randomized, open-label

Mean weight change (% of body weight)

Efficacy analysis, assuming treatment adherence.

REIMAGINE 5: Mean weight change at 60 weeks. Efficacy analysis, assuming treatment adherence.
Treatment & doseChange
CagriSema1.0 mg / 1.0 mg weekly injection−12.4% (novonordisk.com)
Tirzepatide (Mounjaro)5 mg weekly injection−9.1% (novonordisk.com)

Mean HbA1c change (percentage points)

Analysis not stated in the announcement.

REIMAGINE 5: Mean HbA1c change at 60 weeks. Analysis not stated in the announcement.
Treatment & doseChange
CagriSema1.0 mg / 1.0 mg weekly injection−1.71 pp (novonordisk.com)
Tirzepatide (Mounjaro)5 mg weekly injection−1.67 pp (novonordisk.com)

CagriSema 1.0 mg / 1.0 mg was superior to tirzepatide 5 mg for weight reduction and non-inferior for HbA1c reduction.

Neither arm used the dose most people end on: 5 mg is tirzepatide's lowest maintenance dose, and 1.0 mg / 1.0 mg is not the CagriSema dose filed with the FDA. Figures are from Novo Nordisk's announcement, not a peer-reviewed paper. CagriSema is investigational. Study averages do not predict an individual's result.

Read the announcement (novonordisk.com)Sponsor's analysis details (clinicaltrials.gov)Reviewed

TRANSCEND-T2D-2 (prnewswire.com)

Sponsor announcement

Retatrutide vs Ozempic 2 mg in type 2 diabetes

Adults with type 2 diabetes inadequately controlled with metformin, with or without an SGLT2 inhibitor (A1c 7.0% to 10.5%).

1,298 participants · 80 weeks (prnewswire.com/news-releases/lillys-retatrutide-delivered-greater-a1c-reduction-and-more-than-double-the-weight-loss-of-ozempics-highest-approved-dose-in-head-to-head-trial-302921328.html) · Randomized (2:2:1), open-label

Mean HbA1c change (percentage points)

Efficacy analysis, assuming treatment adherence.

TRANSCEND-T2D-2: Mean HbA1c change at 80 weeks. Efficacy analysis, assuming treatment adherence.
Treatment & doseChange
Retatrutide9 mg weekly injection−2.2 pp (prnewswire.com)
Retatrutide12 mg weekly injection−2.2 pp (prnewswire.com)
Semaglutide (Ozempic)2 mg weekly injection−1.8 pp (prnewswire.com)

Mean weight change (% of body weight)

Efficacy analysis, assuming treatment adherence.

TRANSCEND-T2D-2: Mean weight change at 80 weeks. Efficacy analysis, assuming treatment adherence.
Treatment & doseChange
Retatrutide9 mg weekly injection−19.5% (prnewswire.com)
Retatrutide12 mg weekly injection−20.9% (prnewswire.com)
Semaglutide (Ozempic)2 mg weekly injection−9.4% (prnewswire.com)

Both retatrutide doses lowered HbA1c more than Ozempic 2 mg, its highest approved dose, and produced about twice the weight loss. Discontinuation for adverse events was 4.8% (9 mg) and 7.9% (12 mg) vs 2.7%.

Figures are from Lilly's topline announcement, on the analysis that assumes every participant stayed on treatment; not yet peer-reviewed. This trial did not test Ozempic tablets or Wegovy. Retatrutide is investigational. Study averages do not predict an individual's result.

Read the announcement (prnewswire.com)Sponsor's analysis details (clinicaltrials.gov)Reviewed
Understand the evidence

Trial results, with the context that matters

These results come from different studies with different participants, durations, doses, and analyses. They do not establish which treatment is best for you. Medications are listed alphabetically.

Bar scale: 0–30% body-weight reduction. ≈ marks an approximation from kilograms. A trial estimate is not a prediction of your outcome.

  • Dulaglutide

    4.5 mg weekly (Trulicity)

    Reported weight change

    ≈−4.8% (diabetesjournals.org/care/article/44/3/765/138650) (-4.6 kg (~4.8% of the 95.4 kg baseline) at 36 wks · AWARD-11 · 4.5 mg weekly (Trulicity))

    -4.6 kg (~4.8% of the 95.4 kg baseline) at 36 wks

    AWARD-11 (diabetesjournals.org)

    Approximation from kilograms; see trial methods

  • Exenatide

    2 mg weekly (Bydureon)

    Reported weight change

    ≈−4% (diabetesjournals.org/care/article/33/6/1255/27340/DURATION-1-Exenatide-Once-Weekly-Produces) (-4.1 kg (~4% of the 102 kg baseline) at 52 wks · DURATION-1 · 2 mg weekly (Bydureon))

    -4.1 kg (~4% of the 102 kg baseline) at 52 wks

    DURATION-1 (diabetesjournals.org)

    Approximation from kilograms; see trial methods

  • Liraglutide

    3.0 mg daily (Saxenda)

    Reported weight change

    −8% (nejm.org/doi/full/10.1056/NEJMoa1411892) (-8.0% at 56 wks · SCALE Obesity · 3.0 mg daily (Saxenda))

    -8.0% at 56 wks

    SCALE Obesity (nejm.org)

    Analysis not classified; see trial methods

  • Orforglipron

    17.2 mg daily (Foundayo; the label's equivalent of ATTAIN-1's 36 mg dose)

    Reported weight change

    −11.2% (nejm.org/doi/abs/10.1056/NEJMoa2511774) (-11.2% at 72 wks · ATTAIN-1 · 17.2 mg daily (Foundayo; the label's equivalent of ATTAIN-1's 36 mg dose))

    -11.2% at 72 wks

    ATTAIN-1 (nejm.org)

    Accounts for treatment discontinuation

  • Semaglutide

    2.4 mg weekly (Wegovy)

    Reported weight change

    −14.9% (nejm.org/doi/full/10.1056/NEJMoa2032183) (-14.9% at 68 wks · STEP 1 · 2.4 mg weekly (Wegovy))

    -14.9% at 68 wks

    STEP 1 (nejm.org)

    Accounts for treatment discontinuation

  • Tirzepatide

    15 mg weekly (Zepbound)

    Reported weight change

    −20.9% (nejm.org/doi/full/10.1056/NEJMoa2206038) (-20.9% at 72 wks · SURMOUNT-1 · 15 mg weekly (Zepbound))

    -20.9% at 72 wks

    SURMOUNT-1 (nejm.org)

    Accounts for treatment discontinuation

Investigational trial results (5)

Research-stage medicines are not FDA-approved. Trial phase and endpoint are shown with each result.

  • Amycretin

    60 mg weekly (Phase 1b/2a)

    Reported weight change

    −24.3% (thelancet.com/journals/lancet/article/PIIS0140-6736(25)01185-7/abstract) (-24.3% at 36 wks · Phase 1b/2a (subcutaneous) · 60 mg weekly (Phase 1b/2a))

    -24.3% at 36 wks

    Phase 1b/2a (subcutaneous) (thelancet.com)

    Analysis not classified; see trial methods

  • CagriSema

    2.4 mg / 2.4 mg weekly (CagriSema)

    Reported weight change

    −22.7% (prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html) (-22.7% at 68 wks · REDEFINE-1 (Phase 3) · 2.4 mg / 2.4 mg weekly (CagriSema))

    -22.7% at 68 wks

    REDEFINE-1 (Phase 3) (prnewswire.com)

    Estimates effect assuming treatment adherence

    The same trial also reported −20.4% (novonordisk.com/news-and-media/news-and-ir-materials/news-details.html) using the treatment-policy analysis, which accounts for treatment discontinuation. This is the estimate used when matching your priorities.

  • MariTide

    Highest dose, monthly (Phase 2)

    Reported weight change

    −16.2% (nejm.org/doi/full/10.1056/NEJMoa2504214) (-16.2% at 52 wks · Phase 2 obesity · Highest dose, monthly (Phase 2))

    -16.2% at 52 wks

    Phase 2 obesity (nejm.org)

    Accounts for treatment discontinuation

  • Retatrutide

    12 mg weekly (TRIUMPH-1)

    Reported weight change

    −28.3% (prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html) (-28.3% at 80 wks · TRIUMPH-1 (Phase 3) · 12 mg weekly (TRIUMPH-1))

    -28.3% at 80 wks

    TRIUMPH-1 (Phase 3) (prnewswire.com)

    Estimates effect assuming treatment adherence

    The same trial also reported −25% (nejm.org/doi/full/10.1056/NEJMoa2604169) using the treatment-regimen analysis, which accounts for treatment discontinuation. This is the estimate used when matching your priorities.

  • Survodutide

    6.0 mg weekly (Phase 3)

    Reported weight change

    −16.6% (nejm.org/doi/full/10.1056/NEJMoa2600751) (-16.6% at 76 wks · SYNCHRONIZE-1 (Phase 3) · 6.0 mg weekly (Phase 3))

    -16.6% at 76 wks

    SYNCHRONIZE-1 (Phase 3) (nejm.org)

    Estimates effect assuming treatment adherence

    The same trial also reported −13% (nejm.org/doi/full/10.1056/NEJMoa2600751) using the treatment-regimen analysis, which accounts for treatment discontinuation. This is the estimate used when matching your priorities.

Selected weight-change results are not a systematic review of all benefits and risks. Open each medication for additional evidence and safety information. Sources & methodology.

From PubMed

The newest GLP-1 trials and reviews

  • Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial (pubmed.ncbi.nlm.nih.gov/43035096)

    Randomized trial · Tirzepatide · JAMA · Nov 15, 2026 · Kelly AS et al.

  • Disordered Eating Attitudes and Behaviors in Individuals With BMI > 27 kg/m<sup>2</sup> Treated by Semaglutide: A 60-Week Randomized Placebo-Controlled Trial (pubmed.ncbi.nlm.nih.gov/43035836)

    Randomized trial · Semaglutide · Int J Eat Disord · Nov 15, 2026 · Allison KC et al.

  • Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial (pubmed.ncbi.nlm.nih.gov/43033821)

    Randomized trial · Semaglutide · Lancet Diabetes Endocrinol · Nov 14, 2026 · Wharton S et al.

  • Systemic and oral adverse effects of semaglutide reported in randomized controlled trials: a scoping review (pubmed.ncbi.nlm.nih.gov/43034163)

    Systematic review · Semaglutide · BMC Oral Health · Nov 14, 2026 · Muknickas D et al.

  • Kidney effects of tirzepatide across albuminuria, filtration markers, and clinical outcomes: a parent-trial-level systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/43025465)

    Meta-analysis · Tirzepatide · Diabetes Res Clin Pract · Nov 13, 2026 · Li S et al.

  • Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study (pubmed.ncbi.nlm.nih.gov/43014327)

    Randomized trial · Pemvidutide · Lancet Gastroenterol Hepatol · Nov 11, 2026 · Noureddin M et al.

  • First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial (pubmed.ncbi.nlm.nih.gov/43013292)

    Randomized trial · Semaglutide · JAMA Cardiol · Nov 11, 2026 · Marx N et al.

  • Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial (pubmed.ncbi.nlm.nih.gov/43014326)

    Randomized trial · Semaglutide · Lancet · Nov 11, 2026 · Mosenzon O et al.

  • Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial (pubmed.ncbi.nlm.nih.gov/43012507)

    Randomized trial · Tirzepatide · Arthritis Rheumatol · Nov 11, 2026 · Merola JF et al.

  • Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial (pubmed.ncbi.nlm.nih.gov/43003902)

    Randomized trial · Tirzepatide · Nat Med · Nov 9, 2026 · Green DJ et al.

  • Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial (pubmed.ncbi.nlm.nih.gov/43003106)

    Randomized trial · Survodutide · Lancet · Nov 9, 2026 · Bozkurt B et al.

  • Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA) (pubmed.ncbi.nlm.nih.gov/43002161)

    Randomized trial · Orforglipron · JAMA · Nov 9, 2026 · Malhotra A et al.

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Updated automatically

What just changed in the trial registry

  • TrialSemaglutide study now recruiting (was not yet recruiting): GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study (clinicaltrials.gov/study/NCT07588984)
  • TrialResults posted for a Liraglutide study: SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity (clinicaltrials.gov/study/NCT04775082)
  • TrialNew Survodutide study registered: A Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or Obesity (clinicaltrials.gov/study/NCT07940244)
  • TrialVK2735 study now recruiting (was not yet recruiting): Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) (clinicaltrials.gov/study/NCT07868939)
  • TrialVK2735 study now recruiting (was not yet recruiting): Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) (clinicaltrials.gov/study/NCT07868835)
  • TrialNew Semaglutide study registered: Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy Adults (clinicaltrials.gov/study/NCT07935200)
  • TrialSemaglutide study now completed (was active, not recruiting): A Study of BGM0504 in Participants With Type 2 Diabetes (clinicaltrials.gov/study/NCT06716216)
  • TrialNew Semaglutide study registered: GLP-1 Receptor Agonists in the Surgical Patient: Prevalence, Epidemiology, and Pulmonary Complications (clinicaltrials.gov/study/NCT07932119)
  • TrialTirzepatide study now recruiting (was not yet recruiting): Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial (clinicaltrials.gov/study/NCT07734792)
  • TrialNew Tirzepatide study registered: Breath Acetone During Tirzepatide Treatment and Resistance Training in Adults With Obesity (clinicaltrials.gov/study/NCT07931235)

Written from each source's own record as it changes. Every change on GLPcompare

Research activity

Literature counts by ingredient

Europe PMC search matches, listed alphabetically. RCT-tagged publications are not necessarily unique clinical trials. Publication types can overlap, and searches can mention more than one medicine.

  • Aleniglipron

    Investigational

    Counts · Nov 17, 2026 UTC
    RCT-tagged publications2 (europepmc.org/search) (Aleniglipron: RCT-tagged publications)
    Systematic reviews1 (europepmc.org/search) (Aleniglipron: Systematic reviews)
    All search matches18 (europepmc.org/search) (Aleniglipron: All search matches)
  • Amycretin

    Investigational

    Counts · Nov 15, 2026 UTC
    RCT-tagged publications5 (europepmc.org/search) (Amycretin: RCT-tagged publications)
    Systematic reviews1 (europepmc.org/search) (Amycretin: Systematic reviews)
    All search matches86 (europepmc.org/search) (Amycretin: All search matches)
  • CagriSema

    Investigational

    Counts · Nov 14, 2026 UTC
    RCT-tagged publications13 (europepmc.org/search) (CagriSema: RCT-tagged publications)
    Systematic reviews15 (europepmc.org/search) (CagriSema: Systematic reviews)
    All search matches277 (europepmc.org/search) (CagriSema: All search matches)
  • Dulaglutide
    Counts · Nov 16, 2026 UTC
    RCT-tagged publications1,801 (europepmc.org/search) (Dulaglutide: RCT-tagged publications)
    Systematic reviews789 (europepmc.org/search) (Dulaglutide: Systematic reviews)
    All search matches19,123 (europepmc.org/search) (Dulaglutide: All search matches)
  • Exenatide
    Counts · Nov 16, 2026 UTC
    RCT-tagged publications709 (europepmc.org/search) (Exenatide: RCT-tagged publications)
    Systematic reviews618 (europepmc.org/search) (Exenatide: Systematic reviews)
    All search matches13,983 (europepmc.org/search) (Exenatide: All search matches)
  • Liraglutide
    Counts · Nov 15, 2026 UTC
    RCT-tagged publications1,053 (europepmc.org/search) (Liraglutide: RCT-tagged publications)
    Systematic reviews966 (europepmc.org/search) (Liraglutide: Systematic reviews)
    All search matches22,609 (europepmc.org/search) (Liraglutide: All search matches)
  • MariTide

    Investigational

    Counts · Nov 14, 2026 UTC
    RCT-tagged publications1 (europepmc.org/search) (MariTide: RCT-tagged publications)
    Systematic reviews2 (europepmc.org/search) (MariTide: Systematic reviews)
    All search matches82 (europepmc.org/search) (MariTide: All search matches)
  • Mazdutide

    Investigational

    Counts · Nov 16, 2026 UTC
    RCT-tagged publications14 (europepmc.org/search) (Mazdutide: RCT-tagged publications)
    Systematic reviews23 (europepmc.org/search) (Mazdutide: Systematic reviews)
    All search matches267 (europepmc.org/search) (Mazdutide: All search matches)
  • Orforglipron
    Counts · Nov 16, 2026 UTC
    RCT-tagged publications26 (europepmc.org/search) (Orforglipron: RCT-tagged publications)
    Systematic reviews45 (europepmc.org/search) (Orforglipron: Systematic reviews)
    All search matches537 (europepmc.org/search) (Orforglipron: All search matches)
  • Pemvidutide

    Investigational

    Counts · Nov 14, 2026 UTC
    RCT-tagged publications7 (europepmc.org/search) (Pemvidutide: RCT-tagged publications)
    Systematic reviews4 (europepmc.org/search) (Pemvidutide: Systematic reviews)
    All search matches197 (europepmc.org/search) (Pemvidutide: All search matches)
  • Retatrutide

    Investigational

    Counts · Nov 16, 2026 UTC
    RCT-tagged publications22 (europepmc.org/search) (Retatrutide: RCT-tagged publications)
    Systematic reviews52 (europepmc.org/search) (Retatrutide: Systematic reviews)
    All search matches1,005 (europepmc.org/search) (Retatrutide: All search matches)
  • Semaglutide
    Counts · Nov 15, 2026 UTC
    RCT-tagged publications656 (europepmc.org/search) (Semaglutide: RCT-tagged publications)
    Systematic reviews821 (europepmc.org/search) (Semaglutide: Systematic reviews)
    All search matches18,755 (europepmc.org/search) (Semaglutide: All search matches)
  • Survodutide

    Investigational

    Counts · Nov 14, 2026 UTC
    RCT-tagged publications14 (europepmc.org/search) (Survodutide: RCT-tagged publications)
    Systematic reviews32 (europepmc.org/search) (Survodutide: Systematic reviews)
    All search matches531 (europepmc.org/search) (Survodutide: All search matches)
  • Tirzepatide
    Counts · Nov 17, 2026 UTC
    RCT-tagged publications222 (europepmc.org/search) (Tirzepatide: RCT-tagged publications)
    Systematic reviews374 (europepmc.org/search) (Tirzepatide: Systematic reviews)
    All search matches8,108 (europepmc.org/search) (Tirzepatide: All search matches)
  • VK2735

    Investigational

    Counts · Nov 17, 2026 UTC
    RCT-tagged publications1 (europepmc.org/search) (VK2735: RCT-tagged publications)
    Systematic reviews1 (europepmc.org/search) (VK2735: Systematic reviews)
    All search matches33 (europepmc.org/search) (VK2735: All search matches)

These are search matches, not a count of independent trials or proof of benefit. Publication types overlap. Results may include animal research, articles mentioning several ingredients, or retracted work. Counts do not assess study quality and may change after retrieval.

Full sourcing methodology
ClinicalTrials.gov

Most recently completed studies with posted results

The 14 that finished last, by study completion date. Every trial with results we have a page for is listed by name.

Registry · Nov 17, 2026 UTC
Search ClinicalTrials.gov (clinicaltrials.gov/search)
Trial averages do not predict individual outcomes. Review the studied dose, population, duration, analysis, and safety findings with a prescribing clinician. Informational only, not medical advice. Confirm with a clinician and the current FDA label.